Lifesci Capital Initiates Coverage on Eloxx Pharmaceuticals (NASDAQ:ELOX)

Investment analysts at Lifesci Capital assumed coverage on shares of Eloxx Pharmaceuticals (NASDAQ:ELOX) in a note issued to investors on Wednesday,Benzinga reports. The firm set an “outperform” rating and a $40.00 price target on the stock. Lifesci Capital’s price objective indicates a potential upside of 233.33% from the stock’s previous close.

Separately, Guggenheim started coverage on shares of Eloxx Pharmaceuticals in a research report on Monday. They set a “buy” rating and a $43.00 price target for the company. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $41.50.

Eloxx Pharmaceuticals Trading Down 3.8%

ELOX opened at $12.00 on Wednesday. Eloxx Pharmaceuticals has a 52-week low of $11.85 and a 52-week high of $17.50. The stock’s 50 day simple moving average is $17.23. The stock has a market capitalization of $8.26 million, a P/E ratio of -0.78 and a beta of -1,891.27.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.